

## Financial Tear Sheet

### Corporate Profile

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other *in vitro* diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.



OraSure Technologies is the leading supplier of oral-fluid collection devices and *in vitro* diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, *in vitro* diagnostic tests, and other medical devices.



### Usage Terms and Disclaimers

Your usage of this Web site and the information and materials contained therein are subject to the disclaimers and other provisions set forth in the Web site, under Usage Terms, Update Notice and Privacy Policy. Links to these provisions are located at the bottom of each page of this Web site.

### Stock Performance

#### OSUR (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	<b>\$16.86</b>
Change (%)	▲ 0.31 (1.87%)
Volume	3,361,379
52 Week Low	\$8.21
Market Cap	\$1,022,530,743
Rolling EPS	0.52
PE Ratio	31.8588
Shares Outstanding	60,648,324

Data as of 11/22/17 4:00 p.m. ET



## Recent Headlines & Events

11/02/17 - 6:01 a.m.

[OraSure Technologies to Present at the 2017 Canaccord Genuity Medical Technologies & Diagnostics Forum](#)

11/01/17 - 4:00 p.m.

[OraSure Announces 2017 Third Quarter Financial Results](#)


11/01/17 - 6:01 a.m.

[OraSure Technologies to Present at the Stephens 2017 Fall Investment Conference](#)

There are currently no events scheduled.

## Analyst Estimates / Ratings

Mean Recommendation: 1.8



EPS Trend				
		Current	30 Days Ago	90 Days Ago
QTR	Dec 17	0.09	0.08	0.08
QTR	Mar 18	0.08	0.09	0.09
QTR	Jun 18	0.08	0.10	0.10
QTR	Sep 18	0.10	0.11	0.11
FY	Dec 17	0.48	0.48	0.48
FY	Dec 18	0.36	0.40	0.40

## SEC Filings

Filing Date	Form
11/21/17	<a href="#">4</a>
11/21/17	<a href="#">8-K</a>
11/09/17	<a href="#">4</a>
11/09/17	<a href="#">10-Q</a>

## Executive Officers

<a href="#">Douglas A. Michels</a>	President and Chief Executive Officer
<a href="#">Ronald H. Spair</a>	Chief Operating Officer and Chief Financial Officer
<a href="#">Tony Zezzo</a>	Executive Vice President, Business Unit Leader, Infectious Disease
<a href="#">Jack E. Jerrett</a>	Senior Vice President, General Counsel and Secretary
<a href="#">Mark L. Kuna</a>	Senior Vice President, Finance, Controller and Assistant Secretary
<a href="#">Nancy J. McLane</a>	Senior Vice President, Operations
<a href="#">Michael Reed, Ph.D</a>	Senior Vice President, Research and Development and Chief Science Officer
<a href="#">Brian Smith</a>	Senior Vice President, Business Unit leader, Molecular Solutions
<a href="#">Kathleen Weber</a>	Senior Vice President and General Manager, Consumer Products

Data provided by Nasdaq. Minimum 15 minutes delayed.

Minimum 20 minutes delayed